Norway HIV drug trial 'is a step towards cure'

Share this article

The so-called "kick-and-kill" approach to fighting HIV is a promising approach. File photo: AFP
10:27 CET+01:00
A Norwegian drug firm on Tuesday announced an advance in its quest for an HIV cure with a drug combination which seeks to force the virus out of its hiding place and kill it.

A trial with 17 HIV-positive patients yielded a "statistically significant decrease" in the virus, biotech firm Bionor announced.

"This is a major achievement on the path to a functional cure for HIV," Bionor spokesman Jorgen Fischer Ravn told news agency AFP.

There is no cure for the disease AIDS, caused by HIV. but anti-retroviral treatments help people live longer, healthier lives by delaying and subduing symptoms.

In some who undergo treatment, however, the virus takes cover in cells and hides away, only to reemerge once therapy is stopped.

This latency has been one of the biggest hurdles in developing a cure.

"Waking up" the virus and then destroying it -- the so-called "kick-and-kill" approach -- is a promising strategy for ridding patients of HIV.

Bionor's approach involves an anti-cancer drug called romidepsin to wake up the dormant HIV, and a vaccine called Vacc-4x to prime the body's own immune T-cells to recognise and destroy the virus.

"After an activation of the virus, which would normally lead to detectable virus in the blood, Vacc-4x ensured killing of the virus-producing cells to maintain non-detectable or very low levels of virus in the blood in 15 out of 17 patients," said Fischer Ravn.

Story continues below…

No-one has yet been cured of AIDS.

Thirty-nine million people have died of AIDS, according to UN estimates, and about 35 million are living with the immune system-destroying virus today, overwhelmingly in poor countries.

Share this article

From our sponsors

Last chance to vote absentee in the US elections

Election Day in the U.S. is less than a month away, and time is running out for Americans living overseas to vote absentee. Here's what to do before it’s too late.


Popular articles